166 related articles for article (PubMed ID: 37349644)
21. SRPX2 knockdown inhibits cell proliferation and metastasis and promotes chemosensitivity in esophageal squamous cell carcinoma.
He F; Wang H; Li Y; Liu W; Gao X; Chen D; Wang Q; Shi G
Biomed Pharmacother; 2019 Jan; 109():671-678. PubMed ID: 30551519
[TBL] [Abstract][Full Text] [Related]
22. RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway.
Zhang Y; Du J; Duan X; Peng W; Lv L; Chen Z; Zhang Y
Life Sci; 2021 Mar; 269():119064. PubMed ID: 33460665
[TBL] [Abstract][Full Text] [Related]
23. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
24. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
Qiu F; Liu L; Lin Y; Yang Z; Qiu F
Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
[TBL] [Abstract][Full Text] [Related]
25. PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming.
Ma Y; Zhang X; Han X; Hao Z; Ji R; Li J; Guo W; Zhang Y; Guan F; Ma S
Mol Carcinog; 2023 Jun; 62(6):866-881. PubMed ID: 36988347
[TBL] [Abstract][Full Text] [Related]
26. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin.
Hou G; Yang S; Zhou Y; Wang C; Zhao W; Lu Z
J Immunol Res; 2014; 2014():845763. PubMed ID: 24818169
[TBL] [Abstract][Full Text] [Related]
27. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway.
Zhao Y; Ma K; Yang S; Zhang X; Wang F; Zhang X; Liu H; Fan Q
Int J Oncol; 2018 Aug; 53(2):644-658. PubMed ID: 29767234
[TBL] [Abstract][Full Text] [Related]
29. P21-activated kinase 7 mediates cisplatin-resistance of esophageal squamous carcinoma cells with Aurora-A overexpression.
He S; Feng M; Liu M; Yang S; Yan S; Zhang W; Wang Z; Hu C; Xu Q; Chen L; Zhu H; Xu N
PLoS One; 2014; 9(12):e113989. PubMed ID: 25436453
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.
Liu H; Zhang J; Luo X; Zeng M; Xu L; Zhang Q; Liu H; Guo J; Xu L
Oncol Res; 2020 Feb; 28(1):65-73. PubMed ID: 31558183
[TBL] [Abstract][Full Text] [Related]
31. Induction of Immunogenic Cell Death of Esophageal Squamous Cell Carcinoma by 5-Fluorouracil and Cisplatin.
Nishimura J; Deguchi S; Tanaka H; Yamakoshi Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Ohira M
In Vivo; 2021; 35(2):743-752. PubMed ID: 33622867
[TBL] [Abstract][Full Text] [Related]
32. Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting MEK1/2 kinase.
Wang D; Zhang W; Zhang X; Li M; Wu Q; Li X; Zhao L; Yuan Q; Yu Y; Lu J; Zhao J; Dong Z; Liu K; Jiang Y
Mol Carcinog; 2023 Apr; 62(4):517-531. PubMed ID: 36645220
[TBL] [Abstract][Full Text] [Related]
33. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.
Murakami T; Shoji Y; Nishi T; Chang SC; Jachimowicz RD; Hoshimoto S; Ono S; Shiloh Y; Takeuchi H; Kitagawa Y; Hoon DSB; Bustos MA
Mol Oncol; 2021 Apr; 15(4):1069-1087. PubMed ID: 33605536
[TBL] [Abstract][Full Text] [Related]
34. Structure-Guided Design of Ferritin-Platinum Prodrugs for Targeted Therapy of Esophageal Squamous Cell Carcinoma.
Jiang B; Chen X; Wang S; Wang S; Ma S; Lu Y; Ma L; Liang Q; Xiao H; Zhang L; Yan X; Fan K
ACS Nano; 2024 Apr; 18(17):11217-11233. PubMed ID: 38627234
[TBL] [Abstract][Full Text] [Related]
35. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
[TBL] [Abstract][Full Text] [Related]
36. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
[TBL] [Abstract][Full Text] [Related]
37. miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin.
Tian H; Hou L; Xiong YM; Huang JX; She YJ; Bi XB; Song XR
Oncol Rep; 2015 Feb; 33(2):981-9. PubMed ID: 25482044
[TBL] [Abstract][Full Text] [Related]
38. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes.
Zeng RJ; Zheng CW; Gu JE; Zhang HX; Xie L; Xu LY; Li EM
Mol Oncol; 2019 Sep; 13(9):2010-2030. PubMed ID: 31314174
[TBL] [Abstract][Full Text] [Related]
39. PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation.
Zhao Y; Lu Q; Li C; Wang X; Jiang L; Huang L; Wang C; Chen H
Cell Death Dis; 2019 May; 10(5):359. PubMed ID: 31043582
[TBL] [Abstract][Full Text] [Related]
40. CCT4 knockdown enhances the sensitivity of cisplatin by inhibiting glycolysis in human esophageal squamous cell carcinomas.
Fang J; Ma Y; Li Y; Li J; Zhang X; Han X; Ma S; Guan F
Mol Carcinog; 2022 Nov; 61(11):1043-1055. PubMed ID: 36102200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
